MINNEAPOLIS, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced continued commercial momentum for its Aquadex SmartFlow® system, with 31 consoles sold year-to-date in 2026. The Company's year-to-date console performance already exceeds full-year console sales in seven of the past 10 years and puts Nuwellis on pace for one of its top three years for console sales. The expanding installed base comes alongside broader commercial momentum, including 26% year-over-year U.S. revenue growth during the first half of 2026.
“Selling 31 consoles at this point in the year is an important indicator of the commercial progress we are making to expand our installed base of Aquadex systems,” said Mike McCormick, Nuwellis President and Chief Executive Officer. “We are particularly encouraged by our year-to-date performance in that it is being driven by hospitals that recognize the level of patient care associated with Aquadex. This shows that they are making the informed, deliberate decision to incorporate Aquadex into their fluid-management programs.”
Each additional Aquadex console expands the Company's installed base and creates opportunities for recurring utilization of the Company's single-use blood circuits. The Aquadex SmartFlow system consists of a console, catheter, and disposable blood circuit set used to provide controlled ultrafiltration therapy. As the installed base expands and utilization increases, Nuwellis believes console placements can support continued growth in recurring consumable revenue.
Notably, the Company's highest historical console-placement years included the COVID-19 period, when hospitals expanded access to fluid-removal technologies in response to extraordinary critical-care demand. Nuwellis' 2026 performance is being achieved in a normalized hospital environment and reflects continued adoption of Aquadex in the U.S. across the Company's core pediatric, critical-care, and heart-failure markets.
The 2026 console momentum builds upon Nuwellis' broader commercial performance. During the first half of 2026, the Company reported U.S. revenue growth of 26% compared with the prior-year period, with growth across pediatrics, critical care, and heart failure. The Company believes the combination of an expanding installed base, increasing consumable utilization, and continued commercial execution positions the Company to build a larger and more durable recurring-revenue business.
McCormick continued, “Our objective is to build productive Aquadex programs where clinicians use the technology to treat patients effectively when diuretics fail. Expanding the installed base creates the foundation for increasing utilization, recurring circuit revenue and broader adoption of Aquadex therapy.”
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis' strategy includes expanding its portfolio through internally developed technologies and strategic commercial partnerships that broaden its presence across acute and chronic critical care. For more information, visit www.nuwellis.com.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
CORE IR
[email protected]
Media Contact:
CORE PR
[email protected]